新型哮喘生物标志物：趋化因子和类几丁质酶蛋白
2009/08/11
综述的目的：过敏性哮喘是西方常见的肺部疾病，其主要特征为气道炎症和组织重构。若未对哮喘进行早期诊断和特异性治疗，将导致肺功能下降，影响生活质量，甚至因为哮喘发作未得到控制而危及生命。因此，有必要寻找特异性的生物标记物来检测哮喘，以利于有效的临床治疗。
近期研究结果：近期研究发现，趋化因子（C-C模序）配体17和类几丁质酶蛋白YKL-40是哮喘的潜在新型生物标志物。临床试验显示，这些蛋白有助于鉴别哮喘患者和/或判断哮喘的严重性。功能性研究显示，这些分子水平的变化不仅是与疾病有关的附带现象，而且在哮喘的发病过程中起重要作用。
总结：对趋化因子（C-C模序）配体17和YKL-40的研究有助于医生更加准确的诊断和预测哮喘病程，因而能更加个性化对哮喘患者进行治疗。
（林江涛 审校）
Hartl D, et al. Curr Opin Allergy Clin Immunol. 2009 Feb;9(1):60-66.
Novel biomarkers in asthma: chemokines and chitinase-like proteins.
Hartl D, Lee CG, Da Silva CA, Chupp GL, Elias JA.
Section of Pulmonary and Critical Care Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
PURPOSE OF REVIEW: Allergic asthma is a frequent lung disease in Western civilizations and is characterized by airway inflammation and tissue remodeling. Without early diagnosis and specific treatment, asthma results in a loss of lung function, impaired quality of life and the risk to die from uncontrolled asthma attacks. Thus, there is a need for specific biomarkers to detect asthma as soon as possible and to initiate the correct clinical treatment.
RECENT FINDINGS: Recent studies have highlighted the potential role of the chemokine (C-C motif) ligand 17 and the chitinase-like protein YKL-40 as novel biomarkers in asthma. Patient studies suggest that these proteins could be useful to identify asthmatics, to characterize disease severity or both in patients with asthma. Functional studies indicate that these molecules are more than correlated epiphenomena and instead contribute in significant ways to asthma pathogenesis.
SUMMARY: Assessments of chemokine (C-C motif) ligand 17 and YKL-40 may allow physicians to more accurately diagnose and predict the course of asthma and thereby allow therapy to be appropriately tailored for a given patient.
上一篇：
美国胸科学会/欧洲呼吸学会声明：对临床哮喘试验和临床实践中的哮喘控制和恶化进行标准化
下一篇：
过敏性鼻炎的控制和哮喘检测：一种检测工具的建立
